Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine

Articles

Sequencing Systemic Therapy for Advanced HCC

November 24th 2021

Andrea Casadei Gardini, MD, leads the discussion on the optimal sequencing of systemic therapy for advanced HCC.

Optimizing the Selection of Frontline TKIs for Advanced HCC

November 24th 2021

Experts in gastroenterology share their approaches to first-line single-agent and combination TKI therapies for the treatment of advanced HCC.

Updates to First-line Treatment Options for Advanced HCC

November 17th 2021

Andrea Casadei Gardini, MD, presents the case of a 63-year-old man diagnosed with advanced HCC, and the panel reviews available first-line treatment options for patients with advanced HCC.

Is There a Role for Systemic Therapy for Patients With Intermediate HCC?

November 17th 2021

Gastroenterology experts discuss whether there a is a role for systemic therapy for the management of intermediate HCC.

Role of TACE and TARE in the Treatment of HCC

November 10th 2021

Andrea Casadei Gardini, MD, and Stephen L. Chan, MD, examine the use of TACE and TARE-Y90 for the treatment of HCC.

Updates to Adjuvant and Neoadjuvant Therapy in Early HCC

November 10th 2021

Stephen L. Chan, MD, reviews the case of a 72-year-old woman with mild alcoholic cirrhosis and provides insight on the potential role of adjuvant and neoadjuvant therapy for the treatment of HCC.

Final Thoughts on the Future of Liver Cancer

April 8th 2021

A panel of experts lead by Richard S. Finn, MD, provide their final thoughts on the future of advanced unresectable liver cancer.

Challenges of Sequencing and Biomarkers in Hepatocellular Carcinoma

April 8th 2021

Experts provide insight into the challenges of sequencing and biomarkers when treating advanced HCC.

Role of Single Agent IO in Hepatocellular Carcinoma Frontline Therapies

April 8th 2021

A summary of ongoing clinical data that explore the use of frontline single agent immunotherapy in advanced HCC.

HCC Treatment: Emerging Data in IO Combinations

April 1st 2021

Experts discuss emerging data in immunotherapy combination approaches for the treatment of advanced HCC.

Ongoing Data for First-line Combinations in HCC

April 1st 2021

A summary of updates that explore ongoing data from various frontline combinations in unresectable HCC.

Role of TKIs in HCC Treatment

March 25th 2021

An examination of the use of second-line therapies after atezolizumab-bevacizumab, and the role of TKIs for the treatment of advanced HCC.

Treatment Strategies for Childs-Pugh B Disease

March 25th 2021

Experts expand on treatment strategies and sequencing approaches used for Child-Pugh B liver disease.

Considerations for Later Lines of Therapy in HCC Treatment

March 18th 2021

Experts in the field of HCC consider second and third lines of therapy after a patient’s disease state progresses after frontline atezolizumab-bevacizumab.

Personal Experience Using Atezolizumab-Bevacizumab in HCC Treatment

March 18th 2021

Laura M. Kulik, MD, leads a discussion about personal experiences using atezolizumab-bevacizumab and whether clinical trial data reflect real-world experience.

A New Standard of Care for Liver Cancer Treatment

March 11th 2021

A discussion about the recent data from trials that looked at atezolizumab-bevacizumab for the treatment of advanced HCC, and its role as the new standard of care.

Combination Therapy for HCC Treatment

March 11th 2021

Experts discuss recent data surrounding emerging combinations of TACE plus systemic therapies for patients with BCLC stage B or C HCC.

TACE and Systemic Therapy in HCC

March 5th 2021

An in-depth discussion about the role of TACE in combination with systemic therapies for the treatment of HCC.

Recent Findings in Systemic Therapy for Patients With BCLC Stage B HCC 

March 5th 2021

Amit G. Singal, MD, MS, leads a review of recent data around the outcomes of systemic therapy for patients with BCLC stage B HCC.

Practical Considerations of TACE in HCC

February 25th 2021

A panel of experts discuss practical considerations for TACE in patients with unresectable BCLC stage B HCC, as well as define TACE-refractoriness and what to do if a patient fails treatment.